As of close of business last night, Macrogenics Inc’s stock clocked out at $17.19, down -0.41% from its previous closing price of $17.26. In other words, the price has decreased by -$0.07 from its previous closing price. On the day, 963029 shares were traded.
Ratios:
To gain a deeper understanding of MGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.66 and its Current Ratio is at 5.68. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on February 14, 2024, Downgraded its rating to Neutral and sets its target price to $14 from $12 previously.
On December 20, 2023, Citigroup Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $7 to $13.
Guggenheim Upgraded its Neutral to Buy on November 07, 2023, while the target price for the stock was maintained at $12.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 26 when Peters Jeffrey Stuart sold 16,124 shares for $17.22 per share. The transaction valued at 277,655 led to the insider holds 8,895 shares of the business.
Bonvini Ezio sold 3,334 shares of MGNX for $60,012 on Feb 07. The Sr VP, Research & CSO now owns 71,334 shares after completing the transaction at $18.00 per share. On Feb 05, another insider, Peters Jeffrey Stuart, who serves as the Senior VP and General Counsel of the company, sold 76,251 shares for $16.50 each. As a result, the insider received 1,258,142 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 1.07B and an Enterprise Value of 843.96M. As of this moment, Macrogenics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.80 while its Price-to-Book (P/B) ratio in mrq is 5.50. Its current Enterprise Value per Revenue stands at 5.61 whereas that against EBITDA is 44.21.
Stock Price History:
Over the past 52 weeks, MGNX has reached a high of $18.85, while it has fallen to a 52-week low of $4.29. The 50-Day Moving Average of the stock is 13.10, while the 200-Day Moving Average is calculated to be 7.47.
Shares Statistics:
It appears that MGNX traded 975.38K shares on average per day over the past three months and 1.11M shares per day over the past ten days. A total of 61.70M shares are outstanding, with a floating share count of 58.14M. Insiders hold about 6.27% of the company’s shares, while institutions hold 96.02% stake in the company. Shares short for MGNX as of Feb 15, 2024 were 6.38M with a Short Ratio of 6.54, compared to 7.93M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.29% and a Short% of Float of 12.56%.
Earnings Estimates
As of right now, 10 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of $0.38 and a low estimate of -$0.37, while EPS last year was $0.21. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.31 and low estimates of -$0.62.
Analysts are recommending an EPS of between $0.72 and $0.22 for the fiscal current year, implying an average EPS of $0.38. EPS for the following year is -$1.87, with 9 analysts recommending between -$1.03 and -$2.71.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $31.88M. It ranges from a high estimate of $72.4M to a low estimate of $14.46M. As of the current estimate, Macrogenics Inc’s year-ago sales were $73.1M, an estimated decrease of -56.40% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $14.34M, a decrease of -41.50% over than the figure of -$56.40% in the same quarter last year. There is a high estimate of $22.7M for the next quarter, whereas the lowest estimate is $10.46M.
A total of 10 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $120.4M, while the lowest revenue estimate was $62.49M, resulting in an average revenue estimate of $80.1M. In the same quarter a year ago, actual revenue was $151.94M, down -47.30% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $75.5M in the next fiscal year. The high estimate is $137.34M and the low estimate is $19M. The average revenue growth estimate for next year is down -5.70% from the average revenue estimate for this year.
